JQJing Qu

Jing Qu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Jing Qu has a total of 58 co-authors. Here are the top co-authors by number of shared publications:

  • Zhenhua Yang

    School of basic medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    5 shared publications
  • Manman Lu

    School of basic medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    3 shared publications
  • Xiaochuan Dong

    Department of Pathology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

    3 shared publications
  • Yali Qin

    School of Basic Medicine and Forensic Medicine, Henan University of Science & Technology, Luoyang, China

    3 shared publications
  • Chengxuan Yang

    Department of Galactophore, Xinxiang First People's Hospital, Xinxiang, 453000, China

    2 shared publications
  • He Zuo

    School of Basic Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China

    2 shared publications

Latest Publications

  • Open Access

    AMPK phosphorylates WIP1 to promote DNA repair and radioresistance in cancer cells

    by Manman Lu, Xiaochuan Dong, Chunrui Wu, Guisong Wang, Haiyang Wang, Yingli Pan, Yali Qin, Yushuai Song, Hongming Pan, Shenzhi Liu, et al.

    Cell metabolism has a profound impact on maintaining genomic stability. AMP-activated protein kinase (AMPK) is a crucial regulator of cell metabolism and the maintenance of genomic stability. There is increasing evidence that AMPK plays a crucial role in the efficient response to DNA damage (DDR). However, the underlying mechanism is still unclear. Here, we show that glucose deprivation rapidly reduces γH2AX levels, a hallmark of DNA damage. We then found that WIP1, rather than PP2A or PP4C, is the primary phosphatase responsible for dephosphorylating γH2AX under both normal and damaged conditions. Molecular studies have revealed that AMPK directly binds and phosphorylates WIP1 at Thr25 (T25). This action enhances protein stability and the binding ability of WIP1 with γH2AX, likely promoting the enzyme activity of WIP1 and subsequently reducing the level of γH2AX. These processes facilitate DNA damage repair and contribute to the radioresistance of tumor cells. The findings provide experimental evidence of a novel link between metabolic stress and DDR, suggesting that AMPK may promote the resistance of tumor cells to radiation therapy by phosphorylating WIP1.


  • PARP1 interacts with WDR5 to enhance target gene recognition and facilitate tumorigenesis

    by Yali Qin, Xiaochuan Dong, Manman Lu, Lingyun Jing, Qingchuan Chen, Fei Guan, Zhengkai Xiang, Jiaojuan Huang, Chengxuan Yang, Ximiao He, et al.


  • Open Access

    Histone lysine demethylase KDM5B facilitates proliferation and suppresses apoptosis in human acute myeloid leukemia cells through the miR-140-3p/BCL2 axis

    by Jiaojuan Huang, Shuiling Jin, Rongqun Guo, Wei Wu, Chengxuan Yang, Yali Qin, Qingchuan Chen, Ximiao He, Jing Qu, Zhenhua Yang

    The histone lysine demethylase KDM5B is frequently up-regulated in various human cancer cells. However, its expression and functional role in human acute myeloid leukemia (AML) cells remain unclear. Here, we found that the expression level of KDM5B is high in primary human AML cells. We have demonstrated that knocking down KDM5B leads to apoptosis and impairs proliferation in primary human AML and some human AML cell lines. We further identified miR-140-3p as a downstream target gene of KDM5B. KDM5B expression was inversely correlated with the miR-140-3p level in primary human AML cells. Molecular studies showed that silencing KDM5B enhanced H3K4 trimethylation (H3K4me3) at the promoter of miR-140-3p, leading to high expression of miR-140-3p, which in turn inhibited B-cell CLL/lymphoma 2 (BCL2) expression. Finally, we demonstrate that the defective proliferation induced by KDM5B knockdown (KD) can be rescued with the miR-140-3p inhibitor or enhanced by combining KDM5B KD with a BCL2 inhibitor. Altogether, our data support the conclusion that KDM5B promotes tumorigenesis in human AML cells through the miR-140-3p/BCL2 axis. Targeting the KDM5B/miR-140-3p/BCL2 pathway may hold therapeutic promise for treating human AML.


  • Open Access

    Isl1 promotes gene transcription through physical interaction with Set1/Mll complexes

    by Zhe Liu, Weijing Hu, Yali Qin, Li Sun, Lingyun Jing, Manman Lu, Yan Li, Jing Qu, Zhenhua Yang


  • Open Access

    Pharmacological inhibition of MDM4 alleviates pulmonary fibrosis

    by Qianru Mei, Zhenhua Yang, Zhengkai Xiang, He Zuo, Zijing Zhou, Xiaochuan Dong, Ludan Zhang, Wenhui Song, Yi Wang, Qinghua Hu, et al.

    Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease of unknown etiology with no cure. A better understanding of the disease processes and identification of druggable targets will benefit the development of effective therapies for IPF. We previously reported that MDM4 promoted lung fibrosis through the MDM4-p53-dependent pathway. However, it remained unclear whether targeting this pathway would have any therapeutic potential. In this study, we evaluated the efficacy of XI-011, a small molecular inhibitor of MDM4, for treating lung fibrosis. We found that XI-011 significantly reduced MDM4 expression and increased the expression of total and acetylated p53 in primary human myofibroblasts and a murine fibrotic model. XI-011 treatment resulted in the resolution of lung fibrosis in mice with no notable impact on normal fibroblast death or the morphology of healthy lungs. Based on these findings, we propose that XI-011 might be a promising therapeutic drug candidate for treating pulmonary fibrosis.


  • Top Cited Papers
    Open Access

    Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis

    by Qianru Mei, Zhe Liu, He Zuo, Zhenhua Yang&Ast, Jing Qu

    Idiopathic pulmonary fibrosis (IPF) is a progressive, lethal fibrotic lung disease that occurs primarily in middle-aged and elderly adults. It is a major cause of morbidity and mortality. With an increase in life expectancy, the economic burden of IPF is expected to continuously rise in the near future. Although the exact pathophysiological mechanisms underlying IPF remain not known. Significant progress has been made in our understanding of the pathogenesis of this devastating disease in last decade. The current paradigm assumes that IPF results from sustained or repetitive lung epithelial injury and subsequent activation of fibroblasts and myofibroblast differentiation. Persistent myofibroblast phenotype contributes to excessive deposition of the extracellular matrix (ECM) and aberrant lung repair, leading to tissue scar formation, distortion of the alveolar structure, and irreversible loss of lung function. Treatments of patients with IPF by pirfenidone and nintedanib have shown significant reduction of lung function decline and slowing of disease progression in patients with IPF. However, these drugs do not cure the disease. In this review, we discuss recent advances on the pathogenesis of IPF and highlight the development of novel therapeutic strategies against the disease.


  • Open Access

    Targeting mechanosensitive MDM4 promotes lung fibrosis resolution in aged mice

    by Jing Qu, Shan-Zhong Yang, Yi Zhu, Ting Guo, Victor J. Thannickal, Yong Zhou

    Aging is a strong risk factor and an independent prognostic factor for progressive human idiopathic pulmonary fibrosis (IPF). Aged mice develop nonresolving pulmonary fibrosis following lung injury. In this study, we found that mouse double minute 4 homolog (MDM4) is highly expressed in the fibrotic lesions of human IPF and experimental pulmonary fibrosis in aged mice. We identified MDM4 as a matrix stiffness–regulated endogenous inhibitor of p53. Reducing matrix stiffness down-regulates MDM4 expression, resulting in p53 activation in primary lung myofibroblasts isolated from IPF patients. Gain of p53 function activates a gene program that sensitizes lung myofibroblasts to apoptosis and promotes the clearance of apoptotic myofibroblasts by macrophages. Destiffening of the fibrotic lung matrix by targeting nonenzymatic cross-linking or genetic ablation of Mdm4 in lung (myo)fibroblasts activates the Mdm4–p53 pathway and promotes lung fibrosis resolution in aged mice. These findings suggest that mechanosensitive MDM4 is a molecular target with promising therapeutic potential against persistent lung fibrosis associated with aging.


  • Open Access

    Stiff matrix instigates type I collagen biogenesis by mammalian cleavage factor I complex-mediated alternative polyadenylation

    by Zijing Zhou, Jing Qu, Li He, Yi Zhu, Shan-Zhong Yang, Feng Zhang, Ting Guo, Hong Peng, Ping Chen, Yong Zhou

    Alternative polyadenylation (APA) is a widespread and important mechanism in regulation of gene expression. Dysregulation of the 3′ UTR cleavage and polyadenylation represents a common characteristic among many disease states, including lung fibrosis. In this study, we investigated the role of mammalian cleavage factor I–mediated (CFIm-mediated) APA in regulating extracellular matrix production in response to mechanical stimuli from stiffened matrix simulating the fibrotic lungs. We found that stiff matrix downregulated expression of CFIm68, CFIm59 and CFIm25 subunits and promoted APA in favor of the proximal poly(A) site usage in the 3′ UTRs of type I collagen (COL1A1) and fibronectin (FN1) in primary human lung fibroblasts. Knockdown and overexpression of each individual CFIm subunit demonstrated that CFIm68 and CFIm25 are indispensable attributes of stiff matrix–induced APA and overproduction of COL1A1, whereas CFIm did not appear to mediate stiffness-regulated FN1 APA. Furthermore, expression of the CFIm subunits was associated with matrix stiffness in vivo in a bleomycin-induced mouse model of pulmonary fibrosis. These data suggest that stiff matrix instigates type I collagen biogenesis by selectively targeting mRNA transcripts for 3′ UTR shortening. The current study uncovered a potential mechanism for regulation of the CFIm complex by mechanical cues under fibrotic conditions.


  • Open Access

    Calcium in Vascular Smooth Muscle Cell Elasticity and Adhesion: Novel Insights Into the Mechanism of Action

    by Yi Zhu, Jing Qu, Li He, Feng Zhang, Zijing Zhou, Shanzhong Yang, Yong Zhou

    Vascular smooth muscle cells (VSMCs) are the predominant cell type in the arterial wall. These cells play a critical role in maintaining vascular homeostasis including vasoconstriction and vasodilatation through active contraction and relaxation. Dysregulation of VSMC function alters the response of blood vessels to mechanical stress, contributing to the pathogenesis of vascular diseases, particularly atherosclerosis and hypertension. The stiffness of VSMCs is a major regulator of vascular function. Previous studies suggest that intracellular Ca2+ controls the stiffness of VSMCs by a mechanism involving myosin contractile apparatus. More recent studies highlight important functions of cytoskeletal α-smooth muscle actin (α-SMA), α5β1 integrin, and integrin-mediated cell-extracellular matrix (ECM) interactions in Ca2+-dependent regulation of VSMC stiffness and adhesion to the ECM, providing novel insights into the mechanism of calcium action.


  • Open Access

    α6-Integrin alternative splicing: distinct cytoplasmic variants in stem cell fate specification and niche interaction

    by Zijing Zhou, Jing Qu, Li He, Hong Peng, Ping Chen, Yong Zhou

    α6-Integrin subunit (also known as CD49f) is a stemness signature that has been found on the plasma membrane of more than 30 stem cell populations. A growing body of studies have focused on the critical role of α6-containing integrins (α6β1 and α6β4) in the regulation of stem cell properties, lineage-specific differentiation, and niche interaction. α6-Integrin subunit can be alternatively spliced at the post-transcriptional level, giving rise to divergent isoforms which differ in the cytoplasmic and/or extracellular domains. The cytoplasmic domain of integrins is an important functional part of integrin-mediated signals. Structural changes in the cytoplasmic domain of α6 provide an efficient means for the regulation of stem cell responses to biochemical stimuli and/or biophysical cues in the stem cell niche, thus impacting stem cell fate determination. In this review, we summarize the current knowledge on the structural variants of the α6-integrin subunit and spatiotemporal expression of α6 cytoplasmic variants in embryonic and adult stem/progenitor cells. We highlight the roles of α6 cytoplasmic variants in stem cell fate decision and niche interaction, and discuss the potential mechanisms involved. Understanding of the distinct functions of α6 splicing variants in stem cell biology may inform the rational design of novel stem cell-based therapies for a range of human diseases.